StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report released on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Down 1.6 %

NASDAQ CPIX opened at $1.22 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.26 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average is $1.29 and its two-hundred day moving average is $1.43. The company has a market capitalization of $17.31 million, a price-to-earnings ratio of -2.07 and a beta of 0.20. Cumberland Pharmaceuticals has a 1-year low of $1.19 and a 1-year high of $2.36.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.